LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quidel Granted FDA EUA for Lyra Direct SARS-CoV-2 Assay to Allow Direct Sample Processing

By LabMedica International staff writers
Posted on 20 May 2020
Image: Lyra SARS-CoV-2 Assay (Photo courtesy of Quidel Corporation)
Image: Lyra SARS-CoV-2 Assay (Photo courtesy of Quidel Corporation)
Quidel Corporation (San Diego, CA, USA) has received Emergency Use Authorization (EUA) for the Lyra Direct SARS-CoV-2 Assay from the Food and Drug Administration (FDA) to allow direct sample processing.

Under the new EUA, the Lyra Direct SARS-CoV-2 Assay no longer requires an up-front sample extraction. The Lyra Direct SARS-CoV-2 Assay uses a reformulated buffer that replaces the extraction step with a simple 10-minute heat step, saving approximately 50 minutes in processing time. The assay retains its versatility in that it is capable of running on any of seven possible thermocyclers (Applied Biosystems 7500 Standard, Applied Biosystems 7500 Fast, Bio-Rad CFX96 Touch, Qiagen Rotor-Gene Q, Roche LightCycler 480, Roche Cobas z480, and Thermo Fisher QuantStudio 7 Pro).

Separately, the Lyra Direct SARS-CoV-2 Assay received CE Mark on May 8, 2020. The CE Mark allows Quidel to market and sell the Lyra Direct SARS-CoV-2 Assay in Europe, as well as other countries that accept the CE Mark. The assay is currently available for sale in the US under EUA.


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Urine Chemistry Control
Dropper Urine Chemistry Control

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more